Promising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program Initiation

TIPRANKS11-16

Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping the price ta...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483092013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-16 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483092013","market":"us","top_or_hot":-1,"title":"Promising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program Initiation","media":"TIPRANKS","content":"<div>\n<p>Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping the price ta...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Promising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program Initiation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPromising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program Initiation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 00:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping the price ta...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMT","symbol_name":"Sagimet Biosciences Inc.","start_time":0,"source_url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral","article_id":"2483092013","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-sagimet-biosciences-buy-rating-driven-by-denifanstats-clinical-success-and-phase-3-mash-program-initiation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483092013","pubTimestamp":1731687310,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping the price ta...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"SGMT":"Sagimet Biosciences Inc."},"translate_title":"Sagimet Biosciences前景光明：Denifanstat的临床成功和3期MASH计划启动推动了买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMT":1},"content_text":"Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping the price ta...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483092013"}